Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: Work management systems and method are described, specifically providing examples of hotel work management systems and methods. An apparatus may include a work management system that tracks tasks to be done. Each task may be assigned to a user, which the user may access a task list view a remote device. The work management system may be updated in real-time when a task is finished, a task is added, or a task is removed. The work management system may then update the user task list in real-time to allow a user device to see updated tasks on the remote device. Further, the system can track maintenance issues with photographic record(s).

Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Abstract: System and method for load-balancing a plurality of transmission media. A first plurality of packets of a first stream may be transmitted to a second device on a first transmission medium. It may be determined that current medium utilization of the first transmission medium exceeds a first threshold. The first stream may be selected for transmission on both of the first transmission medium and a second transmission medium based on said determining that current medium utilization of the first transmission medium exceeds the first threshold. A second plurality of packets of the first stream may then be transmitted to the second device using both the first transmission medium and the second transmission medium. A first portion of the second plurality of packets may be transmitted on the first transmission medium and a second portion of the second plurality of packets may be transmitted on the second transmission medium.

Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: This invention describes a remmeter that is based on the use of an assembly comprising two or more different-sized hydrogenous moderators, each hydrogenous moderator incorporating a hydrogenous spectroscopic fast neutron detector and a thermal neutron detector in order to provide more accurate neutron dosimetry across a wide range of neutron energies (thermal neutrons to >15 MeV) in a form factor that is lighter than conventional remmeters. The new remmeter utilizes the principle of spectral dosimetry, where the energy or energy distribution of the incident neutrons is first measured and then this energy information (along with the measured fluence) is used to establish the dosimetric quantity using the various fluence-to-dose conversion curves (e.g. H*(10) (ICRP (1997)), NCRP-38 (1971)).

Abstract: Work management systems and method are described, specifically providing examples of hotel work management systems and methods. An apparatus may include a work management system that tracks tasks to be done. Each task may be assigned to a user, which the user may access a task list view a remote device. The work management system may be updated in real-time when a task is finished, a task is added, or a task is removed. The work management system may then update the user task list in real-time to allow a user device to see updated tasks on the remote device. Further, the system can track maintenance issues with photographic record(s).

Abstract: A fuel tank system constructed in accordance to one example of the present disclosure includes a fuel tank, a purge canister, a valve assembly and a bypass means. The valve assembly can be fluidly coupled between the fuel tank and the purge canister and that selectively controls fuel vapor flow between the fuel tank and the purge canister. The bypass means can selectively bypass fuel vapor around at least a portion of the valve assembly from the fuel tank to the purge canister. The bypass means can include a bypass valve.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.

Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compound. Examples of an orthomyxovirus viral infection include an influenza infection.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.